<DOC>
	<DOCNO>NCT01531673</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) effect VX-661 alone coadministered ivacaftor subject CF homozygous heterozygous F508del-CFTR mutation .</brief_summary>
	<brief_title>Study VX-661 Alone Combination With Ivacaftor Subjects Homozygous Heterozygous F508del-Cystic Fibrosis Transmembrane Conductance Regulator ( CFTR ) Mutation</brief_title>
	<detailed_description>This Phase 2 , randomize , multicenter , double-blinded , placebo-controlled , study VX 661 monotherapy , VX 661/ivacaftor co-therapy subject CF homozygous heterozygous F508del CFTR mutation . This study separate seven group : Group 1-7 , respectively . Approximately 180 subject randomize ratio 4:1 ; active drug match placebo group .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female confirm diagnosis CF Must F508delCFTR gene mutation allele ( Groups 1 , 2 , 3 , 4 , 5 , 6 ) . Group 7 subject must F508delCFTR mutation 1 allele , gate mutation G551D second allele physician prescribe 150 mg KalydecoTM q12h ( commercially available ivacaftor ) least 28 day Screening Visit . Forced expiratory volume 1 second ( FEV1 ) 40 % 90 % ( inclusive ) predict normal age , gender , height ( Knudson standard ) screen Weight &gt; 40 kg BMI &gt; 18.5 Subjects childbearing potential sexually active must meet contraception requirement . History illness , opinion investigator , might confound result study pose additional risk administer study drug subject . An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 4 week Study Day 1 . History solid organ hematological transplantation Participation clinical study involve administration either investigational marketed drug within 30 day 5 terminal halflives ( whichever longer ) screen History alcohol , medication , illicit drug abuse within 1 year prior screen Pregnant , breastfeeding , willing follow contraception requirement</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>